Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1089 • ACR Convergence 2020
Intermuscular Adipose Tissue in Patients with Systemic Lupus Erythematosus
Jorge Gamboa¹, Daniel Carranza Leon¹, Rachelle Crescenzi¹, Adriana Marton², Annette Oeser¹, Cecilia Chung¹, Jens Titze², Michelle Ormseth¹ and C. Michael Stein¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Duke NUS Medical School, Singapore, Singapore
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have reduced physical activity and frequently complain of fatigue. Exercise reduces fatigue in patients with SLE; however, the…
Abstract Number: 1265 • ACR Convergence 2020
2019 Lupus Classification Criteria Score Predicting Cost of Future Hospitalizations
Saurav Suman¹, Amna Batool², Joshua Keller² and William Neal Roberts², ¹University of Kentucky, Horseheads, NY, ²University of Kentucky, Lexington, KY
Background/Purpose: The latest 2019 Lupus Classification criteria score (CCS) is based on weighted criteria and has been shown to predict 10-year mortality1. Our previous study…
Abstract Number: 1281 • ACR Convergence 2020
Opioid-Related Encounters as a Predictor of 30-Day Readmissions in Lupus
Christie Bartels¹, Maria Schletzbaum², Yi Chen³ and Amy Kind⁴, ¹University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, ²University of Wisconsin-Madison School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Department of Biostatistics and Medical Informatics, Madison, WI, ⁴University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Health Services and Care Research Program, Geriatrics Division, Madison, WI
Background/Purpose: One in four Medicare hospitalizations with systemic lupus erythematosus (SLE) results in readmission within 30 days, with “injuries and poisonings” as the second most…
Abstract Number: 1297 • ACR Convergence 2020
Lupus Antibodies in Relation to Malignancy
Sarah Huse¹, Jim Oates², Gary Gilkeson³ and Diane Kamen¹, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, SC, Charleston, SC, ³Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) a chronic inflammatory autoimmune disease that has the potential to affect every organ system. Studies have shown increased risk of…
Abstract Number: 1507 • ACR Convergence 2020
Longitudinal Analysis of ANA Assay Performance in SLE from the SLICC Inception Cohort
May Choi¹, Ann Clarke², Karen Costenbader³, Murray Urowitz⁴, John Hanly⁵, Caroline Gordon⁶, Yvan St. Pierre⁷, Sang-Cheol Bae⁸, Juanita Romero-Díaz⁹, F Jorge Sanchez-Guerrero¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Paul Fortin¹⁶, Dafna Gladman¹⁷, Ian Bruce¹⁸, Michelle Petri¹⁹, Ellen M Ginzler²⁰, Mary Anne Dooley²¹, Rosalind Ramsey-Goldman²², Susan Manzi²³, Andreas Jönsen²⁴, Graciela Alarcón²⁵, Ronald F Van Vollenhoven²⁶, Cynthia Aranow²⁷, Meggan Mackay²⁸, Guillermo Ruiz-Irastorza²⁹, S. Sam Lim³⁰, Murat Inanc³¹, Kenneth Kalunian³², Søren Jacobsen³³, Christine Peschken³⁴, Diane Kamen³⁵, Anca Askanase³⁶ and Marvin Fritzler³⁷, ¹Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Calgary, Calgary, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷McGill University, Montreal, Canada, ⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁰University Health Network/Sinai Health system, Toronto, ON, Canada, ¹¹The Research Institute of the McGill University Health Centre, Montreal, ON, Canada, ¹²Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ¹³Centre for Rheumatology, University College London and Department of Rheumatology, University College Hospital, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, ¹⁶CHU de Quebec - Universite Laval, Quebec, Canada, ¹⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁸Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ¹⁹Johns Hopkins University School of Medicine, Timonium, MD, ²⁰SUNY Downstate Health Sciences University, Brooklyn, ²¹University of North Carolina, Chapel Hill, NC, ²²Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²³Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²⁴Lund University, Lund, Sweden, ²⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁶Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²⁷Feinstein Institutes for Medical Research, Manhasset, NY, ²⁸Feinstein Institute for Medical Research, Manhasset, NY, ²⁹Hospital Universitario Cruces, Barakaldo, Spain, ³⁰Emory University, Atlanta, GA, ³¹Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³²University of California San Diego, La Jolla, CA, ³³University of Copenhagen, Copenhagen, Denmark, ³⁴Departments of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ³⁵Medical University of South Carolina, Charleston, SC, ³⁶Columbia University College of Physicians and Surgeons, New York, NY, ³⁷Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-nuclear antibodies (ANA) are important biomarkers for the diagnosis and classification of systemic lupus erythematosus (SLE). However, emerging data from cross-sectional studies suggest variation…
Abstract Number: 1634 • ACR Convergence 2020
Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?
Therese Posas-Mendoza¹, Cara McLeod¹, William Davis² and Robert Quinet², ¹Ochsner Medical Center, New Orleans, LA, ²Dept of Rheumatology, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease characterized by immune-overstimulation and a hyperinflammatory response resulting in cytokine storm and multi-organ failure.1 Secondary HLH…
Abstract Number: 1683 • ACR Convergence 2020
Ready or Not? Measuring Readiness for Transition to Adult Care in Adolescents with JIA & jSLE
Jeanine McColl¹, Teresa Semalulu¹, Arzoo Alam², Steffy Thomas², Julie Herrington³, Jan Willem Gorter², Tania Cellucci², Stephanie Garner², Liane Heale², Mark Matsos², Karen Beattie¹ and Michelle Batthish⁴, ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³The Canadian Arthritis Society, Hamilton, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: Transitioning from pediatric to adult care represents a particularly vulnerable period among patients with JIA and jSLE. The shift to adult care is often…
Abstract Number: 1795 • ACR Convergence 2020
Intracellular Homocysteine and Homocysteine Metabolites in Systemic Lupus Erythematosus (SLE)
George Stojan¹, Jessica Li¹, Amrita Raj², Maureen Kane³ and Michelle Petri⁴, ¹Johns Hopkins University, BALTIMORE, MD, ²Johns Hopkins University, Baltimore, ³University of Maryland School of Pharmacy, Baltimore, ⁴Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: In SLE, homocysteine has been shown to be a potentially modifiable, independent risk factor for stroke and thrombotic events. All previous epidemiological studies used…
Abstract Number: 1814 • ACR Convergence 2020
The Association of Urinary Membrane Attack Complex (C5b-9) with Proteinuria and Glomerular Activity in Lupus Nephritis
Shudan Wang¹, Erica Moore², Brianna Lally³, Beatrice Goilav⁴, Chaim Putterman³ and Anna Broder⁵, ¹Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, ³Albert Einstein College of Medicine, Bronx, NY, ⁴The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁵Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Complement activation is known to play a major role in lupus nephritis (LN). Urinary membrane attack complex (C5b-9) has been shown to correlate with…
Abstract Number: 1830 • ACR Convergence 2020
Adverse Drug Reactions to Trimethoprim-sulfamethoxazole as a Prophylactic Agent Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Antibody as a Possible Risk Factor
Shinji Izuka¹, Hiroyuki Yamashita², Yuko Takahashi² and Hiroshi Kaneko², ¹Devision of Rheumatic Disease, National Center for Global Health and Medicine, Toshima-Ku, Tokyo, Japan, ²Devision of Rheumatic Disease, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Pneumocystis pneumonia (PCP) is a life-threatening infection in immunocompromised patients, including those with connective tissue diseases (CTDs), treated with corticosteroids or immunosuppressive agents. Trimethoprim-sulfamethoxazole…
Abstract Number: 1951 • ACR Convergence 2020
Possible Involvement of Fractalkine/CX3CR1 Axis in Peripheral CD14++CD16+ Monocytes in Disease Development of Patients with Systemic Lupus Erythematosus
Keiko Yoshimoto¹, Katsuya Suzuki¹, Noriyasu Seki², Shuntaro Saito³, Jun Kikuchi¹ and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁴Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan
Background/Purpose: Fractalkine (FKN) binds its receptor, CX3CR1 and accelerates chemotaxis of immune cells by inducing cell surface molecules and mediating adhesion of the cells to…
Abstract Number: 0250 • ACR Convergence 2020
Lupus Nephritis and Renal Outcomes in African-Americans: The Accelerating Medicines Partnership Cohort Experience
Andrea Fava¹, Jessica Li¹, Philip Carlucci², David Wofsy³, Judith James⁴, Chaim Putterman⁵, Betty Diamond⁶, Derek Fine⁷, Jose Monroy-Trujillo⁷, Kristin Haag⁷, Kristina Deonaraine⁸, The Accelerating Medicines Partnership in SLE Network⁹, William Apruzzese¹⁰, Jill Buyon¹¹ and Michelle Petri¹², ¹Johns Hopkins University, Baltimore, MD, ²New York University School of Medicine, New York, NY, ³University of California San Francisco, San Francisco, CA, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Northwell Health, Manhasset, NY, ⁷Johns Hopkins University, Baltimore, ⁸New York University School of Medicine, New York, ⁹Multiple Institutions, Multiple Cities, ¹⁰., Boston, ¹¹Department of Medicine, NYU School of Medicine, New York, NY, ¹²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: The Accelerating Medicines Partnership (AMP) will use multi-omics modalities including single cell RNA sequencing to understand lupus nephritis with the ultimate goal to devise…
Abstract Number: 0267 • ACR Convergence 2020
Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?
Beatriz Tejera Segura¹, Irene Altabás González², Iñigo Rúa-Figueroa³, Natalia Pérez Veiga⁴, Victor del Campo Pérez⁵, Alejandro Olivé-Marqués⁶, Maria Galindo-Izquierdo⁷, Jaime Calvo-Alén⁸, Juan Ovalles-Bonilla⁹, Antonio Fernandez-Nebro¹⁰, Raul Menor Almagro¹¹, Eva Tomero Muriel¹², N. Del-val-del-amo¹³, Maria Esther Uriarte¹⁴, VM Martínez Taboada¹⁵, Jose Luis Andreu Sanchez¹⁶, Alina Lucica Boteanu¹⁷, Francisco Javier Narváez¹⁸, A Morasat¹⁹, Carlos Montilla Morales²⁰, JM Senabre Gallego²¹, Blanca Hernández Cruz²², Mariano Andrés²³, Eva Salgado Pérez²⁴, Mercedes Freire-González²⁵, Sergio Ramon Machin Garcia¹, Clara Moriano²⁶, Lorena Expósito²⁷, Clara E. Perez-Velasquez²⁸, ML Velloso-Feijoo²⁹, Ana Paula Cacheda³⁰, Nuria Lozano Rivas³¹, Gema Bonilla³², Marta Arévalo³³, Inmaculada Jimenez³⁴, VE Quevedo-Vila³⁵, Francisco Manero-Ruiz³⁶, Paloma García de la Peña³⁷, TR Vázquez-Rodríguez³⁸, J Ibáñez-Ruan³⁹, Tatiana Cobo-Ibañez⁴⁰ and Jose Maria Pego-Reigosa⁴¹, ¹Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, ⁴Grupo IRIDIS, Universidad de Vigo, Vigo, Pontevedra, ⁵Hospital Universitario Meixoeiro, Vigo, Vigo, Pontevedra, Spain, ⁶Hospital Germans Trias i Pujol, Barcelona, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ⁹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁰University of Malaga, Malaga, Spain, ¹¹Hospital General Universitario de Jerez de la Frontera, Puerto De Santa Mar�a, Spain, ¹²Hospital Universitario de la Princesa, Madrid, Madrid, Spain, ¹³Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁴Hospital Universitario Donostia, San Sebastian, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁶Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy, ¹⁸Hospital Bellvitge, BARCELONA, Spain, ¹⁹Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ²⁰Hospital Universitario de Salamanca, Salamanca, Spain, ²¹Hospital Marina Baixa, Alicante, Spain, ²²Universidad de Sevilla, Sevilla, Spain, ²³Hospital General Universitario de Alicante, Alicante, Spain, ²⁴Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ²⁵CHU Coruña, Coruña, Spain, ²⁶Complejo Asistencial Universitario de León, León, Spain, ²⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²⁸Basurto University Hospital, Bilbao, Spain, ²⁹Hospital Universitario de Valme, Sevilla, Spain, ³⁰Hospital son LLátzer, Palma de Mallorca, Spain, ³¹Hospital Clínico Universitario Virgen de Arrixaca, Murcia, Spain, ³²Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ³³Hospital Universitari Parc Taulí I3PT, Sabadell, Spain, ³⁴Hospital Clínico San Ceciio Granada, Granada, Spain, ³⁵Hospital Comarcal de Monforte, Lugo, Spain, ³⁶Hospital Universitario Miguel Servet, Zaragoza, Spain, ³⁷Hospital HM, Madrid, Spain, ³⁸Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁹Hospital Povisa, Vigo, Pontevedra, Spain, ⁴⁰Hospital Infanta Sofia, Madrid, Spain, ⁴¹University Hospital of Vigo, Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: To describe the GI manifestations of SLE in the RELESSER (Registry of Systemic Lupus Erythematosus Patients of the Spanish Society of Rheumatology) cohort and…
Abstract Number: 0283 • ACR Convergence 2020
Genome-wide DNA Methylation Analysis in Lupus Keratinocytes Identifies Differential Methylation of Genes That Regulate Apoptosis
Grace Hile¹, Patrick Coit¹, Chang Zeng¹, Rachael Wasikowski², Alex Tsoi², Allison Billi², Johann Gudjonsson³, Amr Sawalha⁴ and J. Michelle Kahlenberg⁵, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann ARbor, ³University of Michigan, Ann ArborUniversity of Michigan, ⁴University of Pittsburgh, Pittsburgh, ⁵Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematous (CLE) is a disfiguring manifestation of systemic LE (SLE), and the pathogenesis remains unclear. However, epidermal regulation of skin inflammation and…
Abstract Number: 0301 • ACR Convergence 2020
Genetic Associations and Polygenic Risk Assessment in Incomplete Lupus Erythematosus
Matthew Slief¹, Jeremy Levin², Susan Macwana¹, Wade DeJager¹, Rebecka Bourn³, Swapan Nath³, Melissa Munroe⁴, Teresa Aberle¹, Patrick Gaffney⁵, Joan Merrill³, Judith James⁶ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²OU Medical Center, Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Patients with incomplete lupus erythematosus (ILE) have features of lupus, but have insufficient criteria for SLE classification. Some ILE patients transition to classified SLE,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].